Stock CYCN CYCLERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
2.267 USD -11.11% Intraday chart for Cyclerion Therapeutics, Inc. -18.17% -32.34%
May. 07 Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 05 Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Number of employees: 1

Managers

Managers TitleAgeSince
Regina Graul PSD
 President 47 Dec. 03
Peter Hecht BRD
 Director/Board Member 60 19-03-31

Members of the board

Members of the board TitleAgeSince
Errol de Souza CHM
 Chairman 70 21-04-25
Terry McGuire BRD
 Director/Board Member 68 19-03-31
Peter Hecht BRD
 Director/Board Member 60 19-03-31
Steven Hyman BRD
 Director/Board Member 71 22-07-24
Michael Higgins BRD
 Director/Board Member 61 Nov. 29
Dina Katabi BRD
 Director/Board Member 52 Nov. 29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,920,591 2,116,493 ( 72.47 %) 210,495 ( 7.207 %) 72.47 %
Stock B 0 351,037 0 0

Shareholders

NameEquities%Valuation
Peter Hecht
13.93 %
377,385 13.93 % 1 M $
Slate Path Capital LP
13.21 %
357,880 13.21 % 955 540 $
MFN Partners Management LP
6.253 %
169,460 6.253 % 452 458 $
Tyndall Management LLC
6.080 %
164,777 6.080 % 439 955 $
Fidelity Management & Research Co. LLC
5.990 %
162,327 5.990 % 433 413 $
Artal Group SA
5.127 %
138,955 5.127 % 371 010 $
Regina Graul
3.701 %
100,303 3.701 % 267 809 $
Errol de Souza
1.845 %
50,000 1.845 % 133 500 $
Terry McGuire
1.550 %
42,018 1.550 % 112 188 $
Geode Capital Management LLC
1.184 %
32,082 1.184 % 85 659 $

Company contact information

Cyclerion Therapeutics, Inc.

Riverview II 245 First Street

02142, Cambridge

+

http://www.cyclerion.com
address Cyclerion Therapeutics, Inc.(CYCN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CYCLERION THERAPEUTICS, INC. Stock Cyclerion Therapeutics, Inc.
-32.34% 6.37M
MODERNA, INC. Stock Moderna, Inc.
+49.41% 57.87B
LONZA GROUP AG Stock Lonza Group AG
+41.65% 40.25B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.72% 39.94B
CELLTRION, INC. Stock Celltrion, Inc.
-5.96% 28.54B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.99% 26.4B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.82% 19.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.35% 12.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.08% 12.23B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.18% 12.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CYCN Stock
  4. Company Cyclerion Therapeutics, Inc.